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Abstract 
Cancer radiotherapy is often complicated by a spectrum of changes in the neighboring bone from mild 
osteopenia to osteoradionecrosis. We previously reported that parathyroid hormone (PTH, 1–34), an 
anabolic agent for osteoporosis, reversed bone structural deterioration caused by multiple 
microcomputed tomography (microCT) scans in adolescent rats. To simulate clinical radiotherapy for 
cancer patients and to search for remedies, we focally irradiated the tibial metaphyseal region of adult 
rats with a newly available small animal radiation research platform (SARRP) and treated these rats with 
intermittent injections of PTH1–34. Using a unique 3D image registration method that we recently 
developed, we traced the local changes of the same trabecular bone before and after treatments, and 
observed that, while radiation caused a loss of small trabecular elements leading to significant decreases 
in bone mass and strength, PTH1–34 preserved all trabecular elements in irradiated bone with 
remarkable increases in bone mass and strength. Histomorphometry demonstrated that SARRP radiation 
severely reduced osteoblast number and activity, which were impressively reversed by PTH treatment. In 
contrast, suppressing bone resorption by alendronate failed to rescue radiation-induced bone loss and to 
block the rescue effect of PTH1–34. Furthermore, histological analyses revealed that PTH1–34 protected 
osteoblasts and osteocytes from radiation-induced apoptosis and attenuated radiation-induced bone 
marrow adiposity. Taken together, our data strongly support a robust radioprotective effect of PTH on 
trabecular bone integrity through preserving bone formation and shed light on further investigations of an 
anabolic therapy for radiation-induced bone damage. 
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Abstract
Cancer radiotherapy is often complicated by a spectrum of changes in the neighboring bone from
mild osteopenia to osteoradionecrosis. We previously reported that parathyroid hormone (PTH, 1–
34), an anabolic agent for osteoporosis, reversed bone structural deterioration caused by multiple
microcomputed tomography (microCT) scans in adolescent rats. To simulate clinical radiotherapy
for cancer patients and to search for remedies, we focally irradiated the tibial metaphyseal region
of adult rats with a newly available small animal radiation research platform (SARRP) and treated
these rats with intermittent injections of PTH1–34. Using a unique 3D image registration method
that we recently developed, we traced the local changes of the same trabecular bone before and
after treatments, and observed that, while radiation caused a loss of small trabecular elements
leading to significant decreases in bone mass and strength, PTH1–34 preserved all trabecular
elements in irradiated bone with remarkable increases in bone mass and strength.
Histomorphometry demonstrated that SARRP radiation severely reduced osteoblast number and
activity, which were impressively reversed by PTH treatment. In contrast, suppressing bone
resorption by alendronate failed to rescue radiation-induced bone loss and to block the rescue
effect of PTH1–34. Furthermore, histological analyses revealed that PTH1–34 protected
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osteoblasts and osteocytes from radiation-induced apoptosis and attenuated radiation-induced bone
marrow adiposity. Taken together, our data strongly support a robust radioprotective effect of PTH
on trabecular bone integrity through preserving bone formation and shed light on further
investigations of an anabolic therapy for radiation-induced bone damage.
Keywords
parathyroid hormone; radiotherapy; image registration; trabecular bone; osteoblast; apoptosis
Introduction
Radiation therapy has more than 100 years of history as a cancer treatment. Each year, about
1 million cancer patients are prescribed radiotherapy in conjunction with surgery and
chemotherapy in order to eliminate tumor cells [1, 2]. The effectiveness of radiotherapy is
based on the radiation dosage delivered to a tumor and is limited by the radiation tolerance
of its surrounding normal tissues. Radiation damage to the skeleton within the radiation field
is a well-recognized late effect, resulting in a spectrum of bone changes from mild
osteopenia to osteoradionecrosis [3–5]. To date, the mechanism of radiation-induced bone
damage has not been fully elucidated. The improved survivorship rate and the increased age
of cancer patients emphasize the importance of understanding this mechanism and
identifying an effective treatment to prevent or reverse such skeletal damage. Currently,
anti-resorptive drugs, such as bisphosphonates, are sometimes used to treat the radiation-
induced osteoporosis, but the evidence of clinical efficacy for this approach is limited and
inconclusive. Moreover, long term use of bisphosphonates is associated with risks, such as
osteonecrosis of the jaw and atypical femur fractures.
Bone is a dynamic organ that undergoes constant remodeling and a balance between
osteoblastic and osteoclastic activities is required to maintain bone homeostasis. The
primary clinical sign of radiation damage to bone is local tissue atrophy, characterized by
loss of functional osteoblasts, marrow adiposity, and microvascular impairments [4, 6].
Preclinical and cell culture studies indicate that radiation damages bone formation by
decreasing osteoblast number, arresting their cell cycle progression, altering their
differentiation ability, and sensitizing them toward apoptosis signals [7–10]. By contrast, the
radiation effect on osteoclasts is still under debate and animal studies have yielded
conflicting results. While some studies clearly showed that radiation at a high dose
diminishes osteoclast number within a week [11–13], other reports indicated an increase in
osteoclast number as early as 3 days after whole-body irradiation [14–16] and found that
anti-resorptive agents, such as risedronate and zoledronic acid, prevent radiation-induced
bone loss in mice [17, 18]. In addition, one study observed a drastic decrease in osteoclast
number followed by a quick rebound in irradiated bone area in a rat model [19].
Intermittent injection of recombinant 1–34 amino-terminal fragment of parathyroid hormone
(PTH1–34) is the only FDA-approved treatment for osteoporosis that stimulates both bone
formation and resorption with a greater effect on bone formation. One of its anabolic
mechanisms is through its suppressive action on the apoptosis of mature osteoblasts.
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Previous studies showed that PTH treatment attenuates the apoptosis of mature osteoblasts
lining the trabecular bone surface in rodents under normal [20, 21] and pathological
conditions, such as diabetes and steroid hormone treatment [22, 23]. Interestingly, Koh et al.
have reported that whole-body radiation at a low dosage augments the anabolic effect of
PTH on bone in mouse pups [24].
We previously reported that daily injections of PTH1–34 prevent the adverse effects of
radiation resulted from multiple longitudinal microcomputed tomography (µCT) scans on
the trabecular bone architecture in young rats [25]. However, this study had limitations.
First, µCT scan does not mimic clinical irradiator because of its low and fixed dosage.
Second, the 1-month-old rats used in this study are adolescent and do not represent most
adult patients receiving radiotherapy. In the present study, we investigated the therapeutic
effect of PTH1–34 on a clinically relevant radiation model by using adult rats and a newly
available small animal radiation research platform (SARRP) that replicates focal clinical
radiotherapy in small animals [26]. A unique 3D image registration approach that we
recently developed [27] was applied to accurately trace the same trabecular bone before and
after radiation and PTH treatments to provide information of structural changes. Combined
with mechanistic cellular changes assessed by histomorphometry and histology, our studies
offer proof-of-principle evidence that PTH1–34 can minimize or fully rescue bone loss
associated with radiotherapy.
Materials and Methods
Rat study design
All animal studies performed in this report were reviewed and approved by the Institutional
Animal Care and Use Committee (IACUC) at the University of Pennsylvania. Three-month-
old female Sprague Dawley rats (Charles River, Wilmington, MA) received a total of 16 Gy
radiation fractionated as two 8 Gy doses delivered on days 1 and 3 to the proximal
metaphyseal region of the right tibiae using SARRP (Xstrahl, Suwanee, GA). The radiation
was delivered in a 13-mm circular collimated field centered at the metaphysis about 4 mm
below the growth plate at a rate of 1.65 Gy/min with the aid of build-in µCT and X-ray. Rats
were then divided into two groups (n=5/group) with similar body weight at the outset of the
study, receiving either vehicle (saline) or human recombinant PTH(1–34, 60 µg/kg/day,
Bachem, Bubendorf, Switzerland) daily subcutaneous injections from day 1 for 28 days. In
vivo µCT of both tibiae were performed at baseline (day 0) and on day 28 prior to
euthanasia. Tibiae were then harvested for histomorphometric analysis. Rats were injected
subcutaneously with 15 mg/kg calcein (Sigma Aldrich, St. Louis, MO) at 2 and 9 days
before necropsy for dynamic bone analysis. The detailed experimental scheme is depicted in
Figure 1. Tibiae from another set of irradiated rats (n=3/time point/group) were harvested at
day 14 and 28 for histology. To test the role of bone resorption, a third set of irradiated rats
were divided into four groups (n=5/group) receiving 1) vehicle (saline, daily); 2) alendronate
(100 µg/kg, twice a week); 3) PTH1–34 (60 µg/kg/day); 4) PTH1–34 (60 µg/kg/day) and
alendronate (100 µg/kg, twice a week). Bilateral tibiae were harvested at day 28 for µCT
analysis. Serum was collected after euthanasia to assess TRACP 5b and osteocalcin levels
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by RatTRAP™ Assay (Immunodiagnostic Systems, Scottsdale, AZ) and Rat osteocalcin
ELISA kit (Biomedical Technologies, Ward Hill MA), respectively.
In vivo µCT scan and analysis
In vivo µCT scan, image analysis of trabecular bone, and finite element analysis (FEA) were
performed as previously described [27]. Briefly, rats were anesthetized by isoflurane and
their right tibiae were immobilized with a customized holder for scanning by an in vivo µCT
system (vivaCT 40, Scanco Medical AG, Brüttisellen, Switzerland) at 10.5 µm nominal
voxel size. Bone voxels of each image were segmented from bone marrow and background
using Gaussian filtering (sigma = 1.2 and support = 2.0) and a global threshold
corresponding to 495 mmHA/cm3. An adaptive thresholding technique was used to
determine a suitable segmentation threshold for all rats in this study. For 3D image
registration, a landmark-initialized, mutual-information-based registration toolkit [28, 29] of
an open source software (National Library of Medicine Insight Segmentation and
Registration Toolkit, USA) [30] was used to register the scans of the proximal tibia at day 0
and day 28. According to the registration, the longitudinal growth rate was determined for
each bone. Trabecular bone parameters and stiffness were calculated from the area 2.5–4
mm below the growth plate at day 0 and its corresponding area at day 28.
Static and dynamic histomorphometry
Left and right tibiae from SARRP-treated rats were dissected at the time of necropsy and
processed for methyl methacrylate embedding. Using a Polycut-S motorized microtome
(Reichert, Heidelberg, Germany), longitudinal sections were cut at 5 µm followed by
Goldner’s trichrome staining for static analysis and at 8 µm without staining for dynamic
measurements. All images were taken with Nikon Eclipse 90i and quantified using Bioquant
Osteo Software (Bioquant Image Analysis, Nashville, TN). The primary indices include the
total tissue area (TV), trabecular bone perimeter (BS), trabecular bone area (BV), osteoblast
surface (Ob.S), osteoblast number (Ob.N), osteoclast surface (Oc.S), single- and double-
labeled surface, interlabel width, osteocyte number, empty lacunae number, and adipocyte
number (Ad.N). The percentages of osteoblast surface (Ob.S/BS), osteoblast number (Ob.N/
BS), osteoclast surface (Oc.S/BS), and mineralizing surface (MS/BS), mineral apposition
rate (MAR, µm/day), and surface-referent bone formation rate (BFR/BS, µm3/µm2/day)
within metaphyseal region were calculated as described by Dempster et al. [31]. Growth
plate thickness was calculated as an average of 12 measurements evenly distributed across
the entire growth plate. Bone marrow adipocytes appear as unstained large circular regions
within the marrow in Goldner’s trichrome-stained sections and their number was counted
manually within a 2 mm2 tissue area located at the center of tibial epiphyseal region.
Histology
Left and right tibiae were fixed in 10% neutralized buffered formalin overnight, decalcified
in 10% EDTA for 21 days, and processed and embedded in paraffin. Five µm-thick sections
were either stained with hematoxylin and eosin (H&E) for general histology or stained with
Apoptag in situ peroxidase kit (EMD Millipore, Billerica, MA) for TUNEL assay to detect
apoptotic osteoblasts.
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Statistics
Data are expressed as means ± standard error (SEM) and analyzed by paired, two tail
Student’s t-test for comparison of the same tibiae before and after radiation and for
comparison of irradiated and non-irradiated contralateral tibiae, and by unpaired Student’s t-
test for comparison of vehicle and PTH-treated samples followed by Bonferroni adjustment
for multiple comparisons using Prism 5 software (GraphPad Software, San Diego, CA).
Values of p<0.05 were considered statistically significant.
Results
3D image registration reveals local trabecular bone loss after SARRP irradiation
To replicate clinical focal radiotherapy, we irradiated the right tibial metaphyseal region in
3-month-old rats by SARRP at a dose of 8 Gy twice (day 1 and 3). For this dose
fractionation schedule, the biologically equivalent dose in 2 Gy fractions assuming an α/β of
3 for late toxicity is approximately 35 Gy. This was designed to mimic the typical femur
dose constraints for whole pelvis intensity modulated radiotherapy for patients with prostate,
rectal, or endometrial cancers. The contralateral tibiae that did not receive radiation, served
as paired controls since their trabecular parameters are similar to age- and gender-matched
left tibiae in normal rats never receiving any radiation exposure (Supplemental Table). Rats
were then separated into two groups, receiving either vehicle or PTH1–34 injections for 4
weeks. At the end of treatment, there were no significant difference in body weight among
vehicle-(259.6±5.9 g), PTH- (259.3±4.3 g) treated rats and their age- and gender-matched
radiation naive rats (266.5±5.0), implicating that SARRP focal radiation does not have
obvious systemic effects.
Unlike large mammals, rats do not close their growth plates or cease their longitudinal bone
growth at skeletal maturity. Since the tibial growth plate was within the radiation field,
histological staining shows that SARRP radiation enlarged the growth plate and caused
disorganization of its columnar chondrocyte arrangement (Fig. 2A, B). These changes led to
a significant 57% reduction in the longitudinal growth rate in irradiated right tibia compared
to non-irradiated left tibia (Fig. 2C). PTH treatment had no effect on this growth damage
caused by SARRP radiation (Fig. 2). The standard µCT approach measuring the trabecular
bone parameters analyzes a metaphyseal area at 2.5–4 mm below the tibial growth plate.
However, due to their different longitudinal growth rate, the same metaphyseal areas in non-
irradiated and irradiated tibiae at day 0 would move to different regions in terms of their
distance to the growth plate at day 28. To overcome this growth issue that does not exist in
adult patients receiving radiotherapy, we performed in vivo µCT scans on bilateral tibiae
twice, at day 0 (before radiation) and day 28 (after radiation), and applied a unique 3D
image registration method recently developed by our group to identify the trabecular
structure at day 28 that matches the metaphyseal area at 2.5–4 mm below the growth plate at
day 0 in the same tibia (Fig. 3A). This approach made it possible to accurately track the
local changes in the same block of trabecular bone after radiation.
Careful examination of the reconstructed 3D µCT images revealed that, while almost all
trabecular elements were preserved in non-irradiated samples during 4 weeks of growth,
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some small trabecular elements were apparently lost after radiation (red circles in Fig. 3B),
implying that radiation shifts the balance of bone remodeling toward more resorption.
Further calculation of structural parameters confirms this observation. As shown in Fig. 3C,
trabecular bone mineral density (BMD) and bone volume fraction (BV/TV) in non-irradiated
tibiae of vehicle-treated rats at day 28 increased dramatically (21% and 51%, respectively)
with increased trabecular thickness (Tb.Th, 30%), unchanged trabecular number (Tb.N) and
trabecular separation (Tb.Sp) compared to its own at day 0. By contrast, trabecular BMD
and BV/TV in irradiated tibiae of vehicle-treated rats at day 28 only increased modestly
(10% and 29%, respectively) compared to its own at day 0. Compared to non-irradiated
contralateral tibiae, BMD and BV/TV from irradiated tibiae were 9% and 14% less,
respectively, at day 28, which was accompanied by a 14% decrease in Tb.N. The increased
structure model index (SMI) in irradiated trabecular bone compared to non-irradiated bone
in vehicle-treated rats at day 28 further confirms the radiation damage to the
microarchitecture of trabecular bone. In addition, analyzing the mechanical property of
trabecular bone by FEA revealed a 51% lower trabecular bone stiffness in irradiated bones
compared to non-irradiated controls (Fig. 3D), suggesting that loss of small trabecular
elements leads to severely impaired mechanical strength after radiation.
PTH1–34 alleviates the local loss of trabecular elements induced by SARRP radiation
Interestingly, a close look at the 3D registered µCT images of PTH-treated bones uncovered
that radiation-induced loss of small trabecular elements did not occur in these rats at day 28
(Fig. 3B). PTH treatment had a great anabolic effect on trabecular bone and increased bone
mass in both non-irradiated and irradiated tibiae substantially to a similar level (Fig. 3C).
This was achieved by increasing Tb.Th in both non-irradiated and irradiated tibiae and
maintaining Tb.N in irradiated tibiae, together with decreasing SMI regardless of radiation.
FEA further indicated that trabecular bone strength was maintained in irradiated bones after
PTH treatment (Fig. 3D). Taken together, these data demonstrate the remarkable ability of
PTH1–34 to alleviate radiotherapy-induced local trabecular bone loss and strength
deterioration.
The preservation of osteoblasts and osteocytes is important for the rescue effect of PTH1–
34 on SARRP radiation-induced bone loss
To understand the cellular mechanisms by which PTH1–34 rescues bone damage after
SARRP radiation, histological analysis was performed on irradiated and contralateral tibiae.
As shown in Fig. 4A, SARRP radiation greatly damaged bone marrow cells, leading to a
decrease in marrow cellularity and an increase in vessel swelling. PTH treatment did not
appear to reverse this damage. Interestingly, while the majority of trabecular bone surfaces
in non-irradiated samples were covered with either bone lining cells or osteoblasts, few bone
surface cells, particularly osteoblasts, were observed in irradiated bone after vehicle
treatment (Fig. 4A, B). By contrast, PTH-treated irradiated bones had more than a 3.9-fold
increase in functional osteoblast number (Ob.N/BS) compared to vehicle-treated irradiated
bones (Fig. 4A, B). Dynamic histomorphometry measurement demonstrated a drastic 78%
decrease in mineral surface (MS/BS) and a nearly complete absence of calcein double-
labeled surface in irradiated bones with vehicle treatment (Fig. 4C). However, PTH
treatment was able to recover the MS/BS, mineral apposition rate (MAR), and bone
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formation rate (BFR) to a similar level as non-irradiated bone with vehicle treatment. These
data clearly indicate that PTH treatment protects the number and activity of osteoblasts from
radiation damage.
We also found that radiation reduced osteoclast number, which was not rescued by PTH
treatment (Fig. 4B). To further investigate the role of bone resorption in these events, we
treated rats with alendronate, an osteoclast inhibitor, right after SARRP radiation for 4
weeks. Biochemical analysis of serum bone resorption (TRAP) and formation (osteocalcin)
markers confirmed that alendronate suppressed osteoclast activity regardless of PTH
treatment and that PTH1–34 elevated osteoblast activity regardless of alendronate treatment
(Fig. 5A). Interestingly, µCT analysis revealed that alendronate did not block either
radiation-induced trabecular bone loss or the rescue effect of PTH (Fig. 5B). These data
strongly suggest that bone formation rather than bone resorption is crucial in mediating
radiation damage to bone structure and support the idea that bone anabolic agent should be
considered when treating radiotherapy-induced osteoporosis.
PTH1–34 reduces radiation-induced apoptosis in osteoblasts and osteocytes
Loss of functional osteoblast is one of the characteristics of radiation damage to bone. To
test whether radiation causes osteoblast apoptosis in vivo and whether PTH1–34 protects
osteoblasts from such cell death, we harvested tibiae at 2 weeks after radiation for TUNEL
staining. As shown in Fig. 6A and B, normal bone had a low level of apoptosis (5%) in
osteoblasts lining trabecular bone surfaces but radiation resulted in a remarkable 6.9-fold
increase to 34% in the vehicle-treated rats. PTH treatment greatly attenuated such damaging
effects on osteoblasts and reduced the apoptosis rate to 10%. Although osteocytes are
relatively radio-resistant compared to osteoblasts, we noticed similar trends in osteocyte
apoptosis under radiation and PTH treatment condition (data not shown). At 4 weeks after
radiation, we observed that radiation resulted in a significant 4.4-fold increase in the
percentage of empty lacunae, a sign of osteocyte cell death, in the vehicle-treated bone (Fig.
6C, D). Similarly, PTH treatment largely blocked such increase, indicating that PTH is able
to protect not only osteoblasts but also osteocytes from radiation-induced cell death.
PTH1–34 partially alleviates radiation-induced bone marrow adiposity
One hallmark for bone marrow damage caused by radiotherapy is increased marrow
adiposity. In our focal radiation model, we found a remarkable increase in adipocyte number
in bone marrow within the irradiated area (Fig. 7A, B). Quantification of adipocyte number
was performed in the tibial epiphyseal region because adipocytes can be morphologically
identified as unstained circular regions in the bone marrow. Interestingly, while radiation led
to a 3.8-fold increase in the number of bone marrow adipocytes per tissue area (Ad.N/TV),
PTH1–34 partially but significantly alleviated this increase, resulting in a 41% decrease in
bone marrow adiposity. These results prove that PTH1–34 inhibits radiation-induced
adipogenesis of bone marrow mesenchymal progenitors, which could be another mechanism
through which PTH maintains bone structure and osteoblasts after radiation.
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Discussion
In this study, we established a radiation-induced bone damage model by focally radiating rat
tibiae with high accuracy at a therapeutic dose using a newly available irradiator (SARRP)
that replicates the focal radiation therapy received by cancer patients. This model mimics
many aspects of radiotherapy damage on bone, such as loss of mineralized bone, decreased
marrow cellularity, loss of vascular integrity, and marrow adiposity. Using this clinically
relevant model, we studied radiation-induced trabecular bone loss and its rescue by PTH1–
34 injections. Structural analyses tracing the same trabecular bone before and after radiation
demonstrated that radiation induces the loss of small trabeculae, leading to significant
reductions in bone mass and mechanical strength, and that PTH1–34 injections are able to
reverse this detrimental effect on bone microarchitecture. Histomorphometry and histology
further proved that radiation drastically damages osteoblast and this damage can be partially
reversed by PTH treatment. We also observed a decrease in osteoclast number after
radiation. The imbalance of radiation effects on these bone cells might lead to relatively
higher osteoclast activity compared to osteoblast activity after radiation, which could have
then caused a loss of small but not large trabecular elements as revealed by 3D image
registration. Osteoblasts are short-lived cells that need to be constantly replenished from
mesenchymal progenitors. Indeed, radiation also shrinks the population of bone marrow
mesenchymal progenitors [13, 25], resulting in bone damage in patients for many years. By
protecting osteoblasts and osteocytes from radiation-induced cell death, PTH1–34 could
have the ability to restore a favorable bone marrow microenvironment for these progenitors
and therefore have a long-term beneficial effect.
A unique strength of the current study is the longitudinal evaluation of the local changes on
the same trabecular structure over the treatment period. In rodents, the changes in bone
structure due to altered local bone activities are often confounded with those resulting from
continuous linear growth of long bones. Since radiation reduces longitudinal bone growth,
we used a specialized image registration and processing scheme, in conjunction with a
customized in vivo µCT imaging protocol, to maximize the accuracy of detecting local bone
structural changes. This technique allows us to exclude the confounding growth issues in
rodents so that the outcomes can be applicable to human. By utilizing this novel technology
with a high image resolution, we were able to track individual trabecular elements over time
to demonstrate the structural mechanisms of radiation damage and PTH’s anabolic effect.
Many previous reports [25, 32–34], including ours, have shown that PTH increases
trabecular number by using cross-sectional comparison to interrogate changes in the
trabecular structure. However, by longitudinal examination of registered trabecular bone
images over time, we identified the thickening of existing trabeculae as the major
microstructural mechanism of PTH’s anabolic action. This technique also allowed us to
determine that, in contrast to the loss of trabecular elements in vehicle-treated bones, main
trabecular elements and their connections are well preserved in PTH-treated ones after
radiation.
Previous rodent studies demonstrated that radiation resulted in a marked decrease in
trabecular bone mass starting from 2 weeks and persisting over 2–3 months [14, 15, 18, 35–
38]. Histomorphometry suggested that decreased osteoblast activity [13, 18, 35, 37] and
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increased osteoclast activity [14–16] were possible causes of this bone loss. Accordingly,
risedronate, an anti-resorptive agent, was found to be effective in blocking this bone loss
[18]. However, these studies exposed either the entire or a large portion of the body to
radiation, which is fundamentally different from the focal radiation used in the clinic due to
two reasons. First, the radiation dose used in these studies was much lower (~2 Gy) than
focal radiotherapy (20–80 Gy) due to a low tolerance of rodents toward whole body
radiation (4–10 Gy). Second, as indicated by reduced body weight and organ size [24, 35,
37], total-body radiation causes systemic side effects, which could have indirect
consequences on osteoclast. A recent report [17] circumvented most of these problems by
radiating entire right limb of mice at 20 Gy and found that zoledronic acid, another anti-
resorptive agent, blocks trabecular bone loss after radiation. Yet no histomorphometry data
were presented in this study. In line with other reports [6, 11–13], we found that focal
radiation at a high dose diminishes both osteoblasts and osteoclasts at 4 weeks post-
radiation. Although some of those studies have shown that radiation decreases osteoclast
number as early as 3–7 days [11–13], we cannot completely exclude the possibility that in
our experiment an early rise of osteoclast number may have contributed to radiation-induced
bone loss. Nevertheless, we found that co-treatment of alendronate does not attenuate
SARRP radiation-induced bone loss or abolish the rescue effect of PTH1–34. We also
demonstrated that the rescue effect of PTH1–34 on radiation-induced bone damage is
dependent on its ability to protect osteoblasts but not osteoclasts after radiation. These data
strongly argue that diminished bone formation but not enhanced bone resorption is a major
contributor to post-radiation bone loss.
The present study provides proof-of-principle evidence that anabolic treatment that
preserves osteoblast lineage cells and stimulates bone formation is a possible therapy for
radiotherapy-induced osteoporosis. However, due to the increased incidence of
osteosarcoma in preclinical rodent studies [39, 40], there are considerable concerns in using
PTH in cancer patients that have received radiation therapy. Nevertheless, results from a
decade of clinical treatment of osteoporosis by PTH failed to establish a causal relationship
between PTH and adult osteosarcoma [41, 42]. Moreover, long-term (3–4 years) clinical
trials of PTH1–34 and 1–84 in children and adults with hypo-parathyroidism have not been
associated with osteosarcoma or other bone tumors [43, 44]. These clinical observations
significantly minimize the concerns of using PTH in cancer patients and promote more
exploratory studies in this field. Indeed, PTH is currently investigated as a therapeutic
treatment for mandible bone regeneration in head and neck cancer patients after surgery and
radiotherapy because it reverses radiation-induced damage and enhances bone regeneration
in a murine mandibular model of distraction osteogenesis [45]. Further studies to understand
the molecular mechanisms of the pro-survival effect of PTH on osteoblasts and osteocytes
will not only provide insights for the therapeutic PTH treatment but also help to identify
additional therapies with fewer concerns.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Focal radiation of proximal tibia in adult rats using a clinically relevant
irradiator (SARRP) causes trabecular bone loss.
• A unique 3D image registration approach demonstrates local structural and
strength damage in trabecular bone after radiation.
• PTH1–34 injections reverse radiation-induced bone loss and structural
deterioration by protecting osteoblasts and osteocytes from apoptosis.
• PTH1–34 treatment also attenuates radiation-induced bone marrow adiposity.
• Our data suggest anabolic treatment that preserves osteoblast lineage cells as a
possible therapy for radiotherapy-induced osteoporosis.
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Figure 1.
A schematic representation of the experimental design to analyze the damaging effect of
SARRP focal radiation on bone and the rescue effect of PTH treatment. L: left tibia; R: right
tibia.
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Figure 2.
Therapeutic dose of radiation impairs longitudinal bone growth regardless of PTH treatment.
(A) Goldner’s trichrome staining of tibial proximal growth plates at day 28 after radiation
and PTH treatments. Double-arrow lines indicate the growth plate. NR: non-irradiated left
tibia; R: irradiated right tibia.
(B) The average thickness of tibial growth plate was quantified.
(C) The tibial longitudinal growth rate within 28 days after radiation and PTH treatments
were calculated based on 3D image registration.
a: p<0.05; b: p<0.01; c: p<0.001 R vs NR. *: p<0.05 vs veh R.
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Figure 3.
PTH reverses trabecular bone loss and strength deterioration caused by SARRP radiation.
(A) Registered 3D whole bone images (top: anterior-posterior view; bottom: superior-
inferior view) of a vehicle-treated non-irradiated rat proximal tibia at day 0 and day 28. A
common region was highlighted in yellow, showing a similar local trabecular structure in
bones that were scanned 4 weeks apart.
(B) 3D reconstructed trabecular images reveals that, while some small trabecular elements
(red circles) were lost after radiation, PTH treatment preserves almost all of them.
(C) µCT measurement of bone structural parameters in the same tibial trabecular area before
(day 0) and after (day 28) SARRP radiation with or without PTH daily treatment. a: p<0.05;
b: p<0.01; c: p<0.001 day 28 vs day 0; *: p<0.05 R vs NR; #: p<0.05 PTH vs veh.
(D) Trabecular bone stiffness was measured by µCT and FEA at day 28. *: p<0.05 vs veh
NR; #: p<0.05 vs veh R.
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Figure 4.
PTH prevents the reductions in osteoblast number and activity caused by SARRP radiation.
(A) H&E staining of tibial trabecular bone sections at day 28 after radiation. Yellow
triangles point to osteoblasts on the trabecular bone surface in the PTH group after radiation.
Blue arrows point to bone marrow blood vessels.
(B, C) Static (B) and dynamic (C) bone histomorphometry of tibial trabecular bone at day 28
after radiation.
*: p<0.05; $: p<0.01; &: p<0.001 R vs NR; #: p<0.05; %: p<0.01; δ: p<0.001 PTH vs veh.
Chandra et al. Page 17
Bone. Author manuscript; available in PMC 2015 October 01.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
Figure 5.
Bone resorption is not essential for SARRP radiation-induced bone loss or the rescue effect
of PTH.
Rats received SARRP radiation (8 Gy twice) to their proximal tibial metaphysis followed by
vehicle, PTH, alendronate (ALN), or a combination of PTH and ALN treatment for 4 weeks.
(A) ELISA analyses of serum concentrations of bone resorption (TRAP) and formation
(osteocalcin) markers at day 28 after radiation. a: p<0.05; b: p<0.01 vs veh; &: p<0.001 vs
PTH; *: p<0.05 vs ALN.
(B) µCT measurement of trabecular bone volume fraction at day 28 after radiation. *:
p<0.05; &: p<0.001 vs its respective NR; #: p<0.05; %: p<0.01; δ: p<0.001 vs its respective
veh.
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Figure 6.
PTH protects osteoblasts and osteocytes from radiation-induced cell death.
(A) TUNEL staining was performed with tibial trabecular bone sections at 2 weeks after
radiation with or without PTH treatment. Red and blue arrows point to TUNEL-positive and
negative osteoblasts, respectively.
(B) The percentage of apoptotic osteoblasts were quantified based on TUNEL staining.
(C) Goldner’s trichrome staining of tibial trabecular bone sections at day 28 shows empty
lacunae (red arrows) in the irradiated samples.
(D) The percentages of dead osteocytes were quantified.
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*: p<0.05; $: p<0.01 R vs NR; %: p<0.01 PTH vs veh.
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Figure 7.
PTH attenuates bone marrow adiposity caused by SARRP radiation.
(A) Goldner’s trichrome staining of tibial sections at day 28 reveals bone marrow adipocytes
(white circles) in the epiphyseal region.
(B) The density of bone marrow adipocytes was quantified. *: p<0.05, $: p<0.01 R vs NR;
#: p<0.05; PTH vs veh.
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